Cancer Incidence and Mortality According to Pre-Existing Heart Failure in a Community-Based Cohort

被引:50
|
作者
Bertero, Edoardo [1 ,2 ,3 ]
Robusto, Fabio [4 ]
Rulli, Eliana [5 ]
D'Ettorre, Antonio [6 ]
Bisceglia, Lucia [7 ]
Staszewsky, Lidia [6 ]
Maack, Christoph [3 ]
Lepore, Vito [6 ]
Latini, Roberto [6 ]
Ameri, Pietro [1 ,2 ]
机构
[1] IRCCS Osped Policlin San Martino, Italian IRCCS Cardiol Network, Cardiovasc Dis Unit, Genoa, Italy
[2] Univ Genoa, Dept Internal Med, Genoa, Italy
[3] Univ Clin Wurzburg, Comprehens Heart Failure Ctr, Wurzburg, Germany
[4] Azienda Sanit Locale TA, Medonline Statte, Taranto, Italy
[5] Ist Ric Farmacol Mario Negri IRCCS, Methodol Clin Res Lab, Dept Oncol, Milan, Italy
[6] Ist Ric Farmacol Mario Negri IRCCS, Dept Cardiovasc Med, Milan, Italy
[7] Reg Hlth Agcy Puglia, Epidemiol & Care Intelligence Area, Bari, Italy
来源
JACC: CARDIOONCOLOGY | 2022年 / 4卷 / 01期
关键词
cardio-oncology; comorbidity; cancer; heart failure; mortality; CARDIOVASCULAR-DISEASE; INCREASED RISK; TUMOR-GROWTH; HOSPITALIZATION; ASSOCIATION; INFARCTION; SURVIVORS;
D O I
10.1016/j.jaccao.2021.11.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND Studies assessing whether heart failure (HF) is associated with cancer and cancer-related mortality have yielded conflicting results.OBJECTIVES This study assessed cancer incidence and mortality according to pre-existing HF in a community-based cohort.METHODS Among individuals $50 years of age from the Puglia region in Italy with administrative health data from 2002 to 2018, no cancer within 3 years before the baseline evaluation, and $5-year follow-up, the study matched 104,020 subjects with HF at baseline with 104,020 control subjects according to age, sex, drug-derived complexity index, Charlson comorbidity index, and follow-up duration. Cancer incidence and mortality were defined based on International Classification of Diseases-Ninth Revision codes in hospitalization records or death certificates.RESULTS The incidence rate of cancer in HF patients and control subjects was 21.36 (95% CI: 20.98-21.74) and 12.42 (95% CI: 12.14-12.72) per 1000 person-years, respectively, with the HR being 1.76 (95% CI: 1.71-1.81). Cancer mortality was also higher in HF patients than control subjects (HR: 4.11; 95% CI: 3.86-4.38), especially in those <70 years of age (HR: 7.54; 95% CI: 6.33-8.98 vs HR: 3.80; 95% CI: 3.44-4.19 for 70-79 years of age; and HR: 3.10; 95% CI: 2.81-3.43 for $80 years of age). The association between HF and cancer mortality was confirmed in a competing risk analysis (subdistribution HR: 3.48; 95% CI: 3.27-3.72). The HF-related excess risk applied to the majority of cancer types. Among HF patients, prescription of high-dose loop diuretic was associated with higher cancer incidence (HR: 1.11; 95% CI: 1.031.21) and mortality (HR: 1.35; 95% CI: 1.19-1.53). CONCLUSIONS HF is associated with an increased risk of cancer and cancer-related mortality, which may be heightened in decompensated states. (J Am Coll Cardiol CardioOnc 2022;4:98-109) (c) 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:98 / 109
页数:12
相关论文
共 50 条
  • [1] CANCER INCIDENCE AND MORTALITY ACCORDING TO PRE-EXISTING HEART FAILURE IN A COMMUNITY-BASED COHORT
    Bertero, E.
    Robusto, F.
    Rulli, E.
    D'Ettore, A.
    Staszewsky, L.
    Maack, C.
    Lepore, V.
    Latini, R.
    Ameri, P.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2022, 24 (SUPPL C)
  • [2] Cancer incidence and mortality according to pre-existing heart failure in a community-based cohort
    Bertero, E.
    Robusto, F.
    Rulli, E.
    D'Ettorre, A.
    Staszewsky, L.
    Maack, C.
    Lepore, V.
    Latini, R.
    Ameri, P.
    EUROPEAN HEART JOURNAL, 2021, 42 : 996 - 996
  • [3] Incidence and mortality of heart failure: A community-based study
    Gomez-Soto, Francisco M.
    Andrey, Jose L.
    Garcia-Egido, Antonio A.
    Escobar, Miguel A.
    Romero, Sotero P.
    Garcia-Arjona, Rocio
    Gutierrez, Jesus
    Gomez, Francisco
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2011, 151 (01) : 40 - 45
  • [4] Increased cancer incidence in patients with pre-existing heart failure: results from a French nationwide cohort study
    Hulot, J. Jean-Sebastien
    Mirabel, M.
    Nevoret, C.
    Domenge, O.
    Empana, J. P.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 153 - 154
  • [5] Increased cancer incidence in patients with pre-existing heart failure: results from a French Nationwide Cohort study
    Hulot, J.
    Mirabel, M.
    Nevoret, C.
    Domenge, O.
    Empana, J. P.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [6] The impact of pre-existing heart failure on pneumonia prognosis: Population-based cohort study
    Thomsen, Reimar W.
    Kasatpibal, Nongyao
    Riis, Anders
    Norgaard, Mette
    Sorensen, Henrik T.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2008, 23 (09) : 1407 - 1413
  • [7] The Impact of Pre-existing Heart Failure on Pneumonia Prognosis: Population-based Cohort Study
    Reimar W. Thomsen
    Nongyao Kasatpibal
    Anders Riis
    Mette Nørgaard
    Henrik T. Sørensen
    Journal of General Internal Medicine, 2008, 23
  • [8] The association between pre-existing heart failure and cancer incidence: A systematic review and meta-analysis
    Barbosa, Carla
    Cabrita, Andre
    Dias, Camila
    Martins, Elisabete
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2024, 43 (07) : 399 - 414
  • [9] Heart Failure Incidence and Mortality in the Southern Community Cohort Study
    Akwo, Elvis A.
    Kabagambe, Edmond K.
    Wang, Thomas J.
    Harrell, Frank E., Jr.
    Blot, William J.
    Mumma, Michael
    Gupta, Deepak K.
    Lipworth, Loren
    CIRCULATION-HEART FAILURE, 2017, 10 (03)
  • [10] History and severity of pre-existing heart failure categorized by medication regimen and mortality from hospitalized pneumonia: Population-based cohort study
    Thomsen, Reimar W.
    Kasatpibal, Nongyao
    Riis, Anders
    Norgaard, Mette
    Sorensen, Henrik T.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 : S236 - S236